Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 317

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

Open access
Thompson, Aliza, Carroll, Kevin, A. Inker, Lesley, Floege, Jürgen, Perkovic, Vlado, Boyer-Suavet, Sonia, W. Major, Rupert, I. Schimpf, Judith, Barratt, Jonathan, Cattran, Daniel C., S. Gillespie, Barbara, Kausz, Annamaria, W. Mercer, Alex, Reich, Heather N., H. Rovin, Brad, West, Melissa, Nachman, Patrick H.·2019·Clinical Journal of the American Society of Nephrology

Abstract

IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve as reliable predictors of a treatment's effect on long-term kidney outcomes in IgAN and be used as a basis for approval. Proteinuria was identified as the most widely recognized and well studied risk factor for progression to ESKD in IgAN. The workgroup performed a critical review of the data on proteinuria reduction as a surrogate end point for a treatment's effect on progression to ESKD in IgAN. Epidemiologic data indicate a strong and consistent relationship between the level and duration of proteinuria and loss of kidney function. Trial-level analyses of data from 13 controlled trials also show an association between treatment effects on percent reduction of proteinuria and treatment effects on a composite of time to doubling of serum creatinine, ESKD, or death. We conclude that data support the use of proteinuria reduction as a reasonably likely surrogate end point for a treatment's effect on progression to ESKD in IgAN. In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2215/cjn.08600718

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 317

Metadata

Authors
Thompson, A., Carroll, K., A. Inker, L., Floege, J., Perkovic, V., Boyer-Suavet, S., W. Major, R., I. Schimpf, J., Barratt, J., Cattran, D. C., S. Gillespie, B., Kausz, A., W. Mercer, A., Reich, H. N., H. Rovin, B., West, M., & Nachman, P. H.
Venue
Clinical Journal of the American Society of Nephrology
Published
2019-01-11
Volume
14
Issue
3
Pages
469-481
ISSN
  • 1555-9041 (ISSN-L)
  • 1555-905X
OpenAlex
W2911011964
Cited by
317
References
44
FWCI
13.12
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. https://app.cochat.ai/papers/10.2215/cjn.08600718
The paper
Thompson, A., Carroll, K., A. Inker, L., Floege, J., Perkovic, V., Boyer-Suavet, S., W. Major, R., I. Schimpf, J., Barratt, J., Cattran, D. C., S. Gillespie, B., Kausz, A., W. Mercer, A., Reich, H. N., H. Rovin, B., West, M., & Nachman, P. H. (2019). Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.08600718

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.